Agenda

 

Approx. 60 minutes

Selecting Treatment Strategies for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Presented on January 27th, 2016

Jennifer R. Brown, MD, PhD

Dana-Farber Cancer Institute

John C. Byrd, MD

The Ohio State University

 

Approx. 60 minutes

Evolving Treatment Options in CLL: Assimilating Emerging Data into Clinical Practice

Presented on January 27th, 2016

Jennifer R. Brown, MD, PhD

Dana-Farber Cancer Institute

John C. Byrd, MD

The Ohio State University

 

Approx. 60 minutes

CRC-Subtype Classification and Clinical Application of Mutation Analysis

Presented on December 16th, 2015

Andrea Cercek, MD

Memorial Sloan Kettering Cancer Center

Bert H. O’Neil, MD

Indiana University Simon Cancer Center

 

Approx. 60 minutes

Personalizing Treatment: A Strategy to Improve Outcomes for Patients with mCRC

Presented on December 16th, 2015

Bert H. O’Neil, MD

Indiana University Simon Cancer Center

Wasif Saif, MD

Tufts University School of Medicine

 

Approx. 60 minutes

Determining Optimal Treatments for Patients with Metastatic Pancreatic Cancer (MPC)

Presented on December 11th, 2015

Eileen M. O'Reilly, MD

Memorial Sloan Kettering Cancer Center

Tanios Bekaii-Saab, MD, FACP

The Ohio State University Comprehensive Cancer Center

 

Approx. 60 minutes

Emerging Targets, Biomarkers, and Imaging Techniques in the Treatment of Patients with Metastatic Pancreatic Cancer (MPC)

Presented on December 11th, 2015

Eileen M. O'Reilly, MD

Memorial Sloan Kettering Cancer Center

Tanios Bekaii-Saab, MD, FACP

The Ohio State University Comprehensive Cancer Center

 

Approx. 60 minutes

Combining Emerging Immunotherapies and Targeted Agents for the Treatment of Melanoma

Presented on September 22nd, 2015

Jeffrey Weber, MD, PhD

Director, Donald A Adam Comprehensive Melanoma Center

Sanjiv Agarwala, MD

St. Luke's University Hospital and Temple University

 

Approx. 60 minutes

A Team-Based Approach to Optimizing Outcomes in Melanoma: Managing Immune Response-Related and Dermatologic Side Effects in Patients being Treated with Novel Therapies

Presented on September 22nd, 2015

Jeffrey Weber, MD, PhD

Director, Donald A Adam Comprehensive Melanoma Center

Sanjiv Agarwala, MD

St. Luke's University Hospital and Temple University

 

Approx. 60 minutes

Testing for Genetic Mutations in Advanced NSCLC

Presented on May 19th, 2015

Mark Socinski, MD

University of Pittsburgh Cancer Institute

Panos Fidias, MD

Thoracic Oncology at University of Arizona Cancer Center at Dignity

 

Approx. 60 minutes

Clinical Challenges in the Personalized Treatment of Advanced NSCLC

Presented on August 12th, 2015

Mark Socinski, MD

University of Pittsburgh Cancer Institute

Panos Fidias, MD

Thoracic Oncology at University of Arizona Cancer Center at Dignity

 

Approx. 60 minutes

Nursing Perspectives for Optimizing Outcomes in Hemophilia Treatment

Presented on October 21st, 2015

Brenda Riske, RN, MSN, MBA, MPA

University of Colorado

Regina B. Butler, RN

Children’s Hospital of Philadelphia

 

Approx. 60 minutes

The War Against Invasive Mycoses: Critical Thinking in High-Risk Patients

Presented on October 20th, 2015

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

The University of Texas MD Anderson Cancer Center

George R. Thompson, MD

University of California, Davis, School of Medicine

Nathan P. Wiederhold, PharmD, FCCP

University of Texas Health Science Center at San Antonio

Thomas Patterson, MD

University of Texas School of Medicine

 

Approx. 60 minutes

The War Against Invasive Mycoses: A Case-Based Approach

Presented on October 20th, 2015

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

The University of Texas MD Anderson Cancer Center

George R. Thompson, MD

University of California, Davis, School of Medicine

Nathan P. Wiederhold, PharmD, FCCP

University of Texas Health Science Center at San Antonio

Thomas Patterson, MD

University of Texas School of Medicine

 

Approx. 35 minutes

The Challenges of Personalized Care for Active Individuals With Hemophilia

Featuring Dr. Mark T. Reding

*This session is not eligible for AMA PRA Category 1 Credits TM

Sponsored by Pfizer, Inc.
Presented October 1st, 2015

Mark T. Reding, MD

University of Minnesota Medical Center

 

Approx. 20 minutes

Explore Anti-Angiogenesis in First Line Metastatic Non-Small Cell Lung Cancer

Featuring Dr. Barbara Gitlitz

*This session is not eligible for AMA PRA Category 1 Credits TM

Sponsored by Genentech Inc.
Presented on August 12th, 2015

Barbara Gitlitz, MD

Keck Medicine of University of Southern California

 

Approx. 30 minutes

Assessing Survival: What's the Endpoint?

Featuring Drs. Linda T. Vahdat and Scott D. Christensen

*This session is not eligible for AMA PRA Category 1 Credits TM

Sponsored by Eisai Inc.
Presented on May 19th, 2015

Linda T. Vahdat, MD

Weill Cornell Medical College

Scott D. Christensen, MD

UC Davis Cancer Care Network